Analyzing the tumor environment in gastric cancer patients receiving immunotherapy and chemotherapy
Using Single-cell Sequencing to Explore Tumor Microenvironment in Gastric Cancer Patients Treated With Combined Immunotherapy and Chemotherapy
This study looks at how the tumor environment changes in gastric cancer patients receiving both immunotherapy and chemotherapy to see what makes the treatment work better for some people than others.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 28 (estimated) |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Sponsor | Chinese PLA General Hospital Academic / other |
| Drugs / interventions | nivolumab, sintilimab, chemotherapy, immunotherapy |
| Locations | 1 site (Beijing, Beijing) |
| Trial ID | NCT06202781 on ClinicalTrials.gov |
What this trial studies
This observational study aims to analyze the tumor microenvironment (TME) in gastric cancer patients who are treated with a combination of immunotherapy and chemotherapy. It will profile the TME before and after treatment to understand the mechanisms behind the efficacy of this combined approach. Additionally, the study will compare patients with different treatment responses to identify crucial factors that influence treatment outcomes.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 to 70 with advanced gastric adenocarcinoma who are eligible for specific chemotherapy and immunotherapy treatments.
Not a fit: Patients with a history of other malignancies, prior treatments, or those not receiving the specified chemotherapy and immunotherapy will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide insights that enhance the effectiveness of combined immunotherapy and chemotherapy for gastric cancer patients.
How similar studies have performed: While this study focuses on a specific combination of treatments, similar approaches in analyzing the tumor microenvironment have shown promise in other cancer types.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Non-bedridden, aged 18 to 70 years old; * Eastern Cooperative Oncology Group (ECOG) score is 0 to 1; * Histologically confirmed gastric adenocarcinoma with evaluable lesions based on RECIST 1.1; * Advanced gastric cancer; * Ready for receiving S-1 plus oxaliplatin chemotherapy and either nivolumab or sintilimab Exclusion Criteria: * History of other malignant diseases in the last 5 years; * Prior chemotherapy, radiotherapy or immunotherapy; * Not receiving S-1 plus oxaliplatin chemotherapy and either nivolumab or sintilimab.
Where this trial is running
Beijing, Beijing
- Chinese PLA General Hospital — Beijing, Beijing, China (Recruiting)
Study contacts
- Study coordinator: Xinxin Wang, MD
- Email: wangxx301@outlook.com
- Phone: 0086-10-938328
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.